Emerging pharmacological strategies for the management of chemotherapy-induced peripheral neurotoxicity (CIPN), based on novel CIPN mechanisms

References

• Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69:363–385.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Alberti P, Argyriou AA, et al.; Toxic Neuropathy Consortium of the Peripheral Nerve Society. Chemotherapy-induced peripheral neurotoxicity: a multifaceted, still unsolved issue. J Peripher Nerv Syst. 2019;24(Suppl 2):S6–12.
   PubMedGoogle Scholar
• Cavaletti G, Cornblath DR, Merkies ISJ, et al. Patients’ and physicians’ interpretation of chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2019;24:111–119.
   PubMed Web of Science ®Google Scholar
• Dorsey SG, Kleckner IR, Barton D, et al. The national cancer institute clinical trials planning meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy. J Natl Cancer Inst. 2019;111:531–537.
   PubMedGoogle Scholar
• Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155:2461–2470.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Park SB, Islam B, et al.; Toxic Neuropathy Consortium (TNC). Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings. J Neurol Neurosurg Psychiatry. 2019;90:1361–1369.
   PubMed Web of Science ®Google Scholar
• Song X, Wilson KL, Kagan J, et al. Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis. Ther Adv Hematol. 2019;10:2040620719839025.
   Web of Science ®Google Scholar
• Tamburin S, Park SB, Alberti P, et al. Taxane and epothilone-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019;24(Suppl2):S40–51.
   PubMedGoogle Scholar
• Islam B, Lustberg M, Staff NP, et al. Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019;24(Suppl2):S63–73.
   PubMedGoogle Scholar
• Bechakra M, Nieuwenhoff MD, van Rosmalen J, et al. Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain. Mol Pain. 2018;14:1744806918797042.
   Web of Science ®Google Scholar
• Colvin LA. Chemotherapy-induced peripheral neuropathy: where are we now? Pain. 2019;160(Suppl1):S1–10.
   PubMedGoogle Scholar
• Staff NP, Cavaletti G, Islam B, et al. Platinum-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019;24(Suppl2):S26–39.
   PubMedGoogle Scholar
• Robertson J, Raizer J, Hodges JS, et al. Risk factors for the development of paclitaxel-induced neuropathy in breast cancer patients. J Peripher Nerv Syst. 2018;23:129–133.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Till C, Wright JD, et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in southwest oncology group clinical trials. J Clin Oncol. 2016;34:3014–3022.
   PubMed Web of Science ®Google Scholar
• Greenwald MK, Ruterbusch JJ, Beebe-Dimmer JL, et al. Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a medicare population. Cancer. 2019;125:269–277.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Bruna J, Genazzani AA, et al. Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. Nat Rev Neurol. 2017;13:492–504.
   PubMed Web of Science ®Google Scholar
• Park SB, Alberti P, Kolb NA, et al. Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2019;24(Suppl2):S13–25.
   PubMedGoogle Scholar
• Calls A, Carozzi V, Navarro X, et al. Pathogenesis of platinum-induced peripheral neurotoxicity: insights from preclinical studies. Exp Neurol. 2020;325:113141.
   PubMed Web of Science ®Google Scholar
• Staff NP, Fehrenbacher JC, Caillaud M, et al. Pathogenesis of paclitaxel-induced peripheral neuropathy: a current review of in vitro and in vivo findings using rodent and human model systems. Exp Neurol. 2020;324:113121.
   PubMed Web of Science ®Google Scholar
• Kober KM, Olshen A, Conley YP, et al. Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel-induced peripheral neuropathy in breast cancer survivors. Mol Pain. 2018;14:1744806918816462.
   Web of Science ®Google Scholar
• Trecarichi A, Flatters SJL. Mitochondrial dysfunction in the pathogenesis of chemotherapy-induced peripheral neuropathy. Int Rev Neurobiol. 2019;145:83–126.
   PubMed Web of Science ®Google Scholar
• Makker PG, Duffy SS, Lees JG, et al. Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. PLoS One. 2017;12:e0170814.
   PubMed Web of Science ®Google Scholar
• Geisler S, Doan RA, Strickland A, et al. Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice. Brain. 2016;139:3092–3108.
   PubMed Web of Science ®Google Scholar
• Pease-Raissi SE, Pazyra-Murphy MF, Li Y, et al. Paclitaxel reduces axonal bclw to initiate IP3R1-dependent axon degeneration. Neuron. 2017;96:373–386.
   PubMed Web of Science ®Google Scholar
• Bruna J, Velasco R. Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathy. Neural Regen Res. 2018;13:775–778.
   PubMed Web of Science ®Google Scholar
• Bruna J, Videla S, Argyriou AA, et al. Efficacy of a novel sigma-1 receptor antagonist for oxaliplatin-induced neuropathy: a randomized, double-blind, placebo-controlled phase IIa clinical trial. Neurotherapeutics. 2018;15:178–189.
   PubMed Web of Science ®Google Scholar
• Lisse TS, Middleton LJ, Pellegrini AD, et al. Paclitaxel-induced epithelial damage and ectopic MMP-13 expression promotes neurotoxicity in zebrafish. Proc Natl Acad Sci U S A. 2016;113:E2189‐98.
   PubMed Web of Science ®Google Scholar
• Janes K, Little JW, Li C, et al. The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1. J Biol Chem. 2014;289:21082–21097.
   PubMed Web of Science ®Google Scholar
• Stockstill K, Doyle TM, Yan X, et al. Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain. J Exp Med. 2018;215:1301–1313.
   PubMed Web of Science ®Google Scholar
• Alé A, Bruna J, Morell M, et al. Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model. Exp Neurol. 2014;253:165–173.
   PubMed Web of Science ®Google Scholar
• Meregalli C, Marjanovic I, Scali C, et al. High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats. J Neuroinflammation. 2018;15:232.
   PubMed Web of Science ®Google Scholar
• Chua KC, Xiong C, Ho C, et al. Genome-wide meta-analysis validates a role for S1PR1 in microtubule targeting agent-induced sensory peripheral neuropathy. Clin Pharmacol Ther. 2020. DOI:10.1002/cpt.1958
   PubMed Web of Science ®Google Scholar
• Sprowl JA, Ong SS, Gibson AA, et al. A phosphotyrosine switch regulates organic cation transporters. Nat Commun. 2016;7:10880.
   PubMed Web of Science ®Google Scholar
• Stojanovska V, McQuade R, Rybalka E, et al. Neurotoxicity associated with platinum-based anti-cancer agents: what are the implications of copper transporters? Curr Med Chem. 2017;24:1520–1536.
   PubMed Web of Science ®Google Scholar
• Fujita S, Hirota T, Sakiyama R, et al. Identification of drug transporters contributing to oxaliplatin-induced peripheral neuropathy. J Neurochem. 2019;148:373–385.
   PubMed Web of Science ®Google Scholar
• Leblanc AF, Sprowl JA, Alberti P, et al. OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. J Clin Invest. 2018;128:816–825.
   PubMed Web of Science ®Google Scholar
• Stage TB, Mortensen C, Khalaf S, et al. P-glycoprotein inhibition exacerbates paclitaxel neurotoxicity in neurons and cancer patients. Clin Pharmacol Ther. 2020 Apr 10. DOI:10.1002/cpt.1847
   Web of Science ®Google Scholar
• Grube M, Ameling S, Noutsias M, et al. Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy. Am J Pathol. 2011;178:2547–2559.
   PubMed Web of Science ®Google Scholar
• Fu C, Gombos DS, Lee J, et al. Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget. 2017;8:58709–58727.
   PubMedGoogle Scholar
• Ferdousi M, Azmi S, Petropoulos IN, et al. Corneal confocal microscopy detects small fibre neuropathy in patients with upper gastrointestinal cancer and nerve regeneration in chemotherapy induced peripheral neuropathy. PLoS One. 2015;10:e0139394.
   PubMed Web of Science ®Google Scholar
• Kim HS, Guo C, Thompson EL, et al. APE1, the DNA base excision repair protein, regulates the removal of platinum adducts in sensory neuronal cultures by NER. Mutat Res. 2015;779:96–104.
   PubMed Web of Science ®Google Scholar
• Kelley MR, Wikel JH, Guo C, et al. Identification and characterization of new chemical entities targeting apurinic/apyrimidinic endonuclease 1 for the prevention of chemotherapy-induced peripheral neuropathy. J Pharmacol Exp Ther. 2016;359(2):300–309.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Manojlovic N, Pfeiffer P, et al. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx(®)): a placebo-controlled randomised phase II study (PLIANT). Acta Oncol. 2018;57:393–402.
   PubMed Web of Science ®Google Scholar
• Areti A, Komirishetty P, Kumar A. Carvedilol prevents functional deficits in peripheral nerve mitochondria of rats with oxaliplatin-evoked painful peripheral neuropathy. Toxicol Appl Pharmacol. 2017;322:97–103.
   PubMed Web of Science ®Google Scholar
• Bordet T, Berna P, Abitbol JL, et al. Olesoxime (TRO19622): a novel mitochondrial-targeted neuroprotective compound. Pharmaceuticals (Basel). 2010;3:345–368.
   PubMedGoogle Scholar
• Aureli M, Mauri L, Ciampa MG, et al. GM1 ganglioside: past studies and future potential. Mol Neurobiol. 2016;53:1824–1842.
   PubMed Web of Science ®Google Scholar
• Ferrari G, Anderson BL, Stephens RM, et al. Prevention of apoptotic neuronal death by GM1 ganglioside. Involvement of Trk neurotrophin receptors. J Biol Chem. 1995;270:3074–3080.
   PubMed Web of Science ®Google Scholar
• San Gil R, Ooi L, Yerbury JJ, et al. The heat shock response in neurons and astroglia and its role in neurodegenerative diseases. Mol Neurodegener. 2017;12:65.
   PubMed Web of Science ®Google Scholar
• Zhu J, Chen W, Mi R, et al. Ethoxyquin prevents chemotherapy-induced neurotoxicity via Hsp90 modulation. Ann Neurol. 2013;74:893–904.
   PubMed Web of Science ®Google Scholar
• Zhu J, Carozzi VA, Reed N, et al. Ethoxyquin provides neuroprotection against cisplatin-induced neurotoxicity. Sci Rep. 2016;6:28861.
   PubMed Web of Science ®Google Scholar
• Mendillo ML, Santagata S, Koeva M, et al. HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell. 2012;150:549–562.
   PubMed Web of Science ®Google Scholar
• Shevtsov M, Multhoff G, Mikhaylova E, et al. Combination of anti-cancer drugs with molecular chaperone inhibitors. Int J Mol Sci. 2019;20:5284.
   Web of Science ®Google Scholar
• Hershman DL, Lacchetti C, Dworkin RH, et al.; American Society of Clinical Oncology. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2014;32:1941–1967.
   PubMed Web of Science ®Google Scholar
• Smith EM, Pang H, Cirrincione C, et al.; Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309:1359–1367.
   PubMed Web of Science ®Google Scholar
• Barton DL, Wos EJ, Qin R, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer. 2011;19:833–841.
   PubMed Web of Science ®Google Scholar
• Karlsson JOG, Jynge P. Is it possible to draw firm conclusions from the PLIANT trial? Acta Oncol. 2018;57:862–864.
   PubMed Web of Science ®Google Scholar
• Su Y, Huang J, Wang S, et al. The effects of ganglioside-monosialic acid in taxane-induced peripheral neurotoxicity in patients with breast cancer: a randomized trial. J Natl Cancer Inst. 2020;112:55–62.
   PubMedGoogle Scholar
• Wang DS, Wang ZQ, Chen G, et al. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer. Cancer Med. 2020;9:151–159.
   PubMed Web of Science ®Google Scholar
• Vela JM, Merlos M, Almansa C. Investigational sigma-1 receptor antagonists for the treatment of pain. Expert Opin Investig Drugs. 2015;24:883–896.
   PubMed Web of Science ®Google Scholar
• Aghili M, Zare M, Mousavi N, et al. Efficacy of gabapentin for the prevention of paclitaxel induced peripheral neuropathy: a randomized placebo controlled clinical trial. Breast J. 2019;25:226–231.
   PubMed Web of Science ®Google Scholar
• Shinde SS, Seisler D, Soori G, et al. Can pregabalin prevent paclitaxel-associated neuropathy?-An ACCRU pilot trial. Support Care Cancer. 2016;24:547–553.
   PubMed Web of Science ®Google Scholar
• Salehifar E, Janbabaei G, Hendouei N, et al. Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy: a randomized controlled trial. Clin Drug Investig. 2020;40:249–257.
   PubMed Web of Science ®Google Scholar
• Kim BS, Jin JY, Kwon JH, et al. Efficacy and safety of oxycodone/naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea. Asia Pac J Clin Oncol. 2018;14:e448–54.
   PubMed Web of Science ®Google Scholar
• Song SY, Ko YB, Kim H, et al. Effect of serotonin-norepinephrine reuptake inhibitors for patients with chemotherapy-induced painful peripheral neuropathy: a meta-analysis. Medicine (Baltimore). 2020;99:e18653.
   PubMed Web of Science ®Google Scholar
• Farshchian N, Alavi A, Heydarheydari S, et al. Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy. Cancer Chemother Pharmacol. 2018;82:787–793.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Kalofonou F, Litsardopoulos P, et al. Real world, open label experience with lacosamide against acute painful oxaliplatin-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2020;25:178–183.
   PubMed Web of Science ®Google Scholar
• Pfeiffer P, Qvortrup C, Muro K, et al. The Global POLAR program: calmangafodipir used on top of modified FOLFOX6 (5-FU/FA and oxaliplatin) to prevent chemotherapy induced peripheral neuropathy. J Clin Oncol. 2018;37(4suppl):TPS722.
   Google Scholar
• PLEDPharma Media Release, STO: PLED. [ cited 2020 July 10]. Available from: https://www.pledpharma.com/mfn_news/pledpharma-to-close-polar-phase-3-program-in-the-third-quarter/
   Google Scholar
• Geisler S, Doan RA, Cheng GC, et al. Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program. JCI Insight. 2019;4(17):e129920.
   PubMed Web of Science ®Google Scholar
• Hamity MV, White SR, Walder RY, et al. Nicotinamide riboside, a form of vitamin B3 and NAD+ precursor, relieves the nociceptive and aversive dimensions of paclitaxel-induced peripheral neuropathy in female rats. Pain. 2017;158:962–972.
   PubMed Web of Science ®Google Scholar
• Angeli A, Di Cesare Mannelli L, Ghelardini C, et al. Benzensulfonamides bearing spyrohydantoin moieties act as potent inhibitors of human carbonic anhydrases II and VII and show neuropathic pain attenuating effects. Eur J Med Chem. 2019;177:188–197.
   PubMed Web of Science ®Google Scholar
• van den Heuvel SAS, van der Wal SEI, Smedes LA, et al. Intravenous lidocaine: old-school drug, new purpose-reduction of intractable pain in patients with chemotherapy induced peripheral neuropathy. Pain Res Manag. 2017;2017:8053474.
   PubMed Web of Science ®Google Scholar
• Favre-Guilmard C, Auguet M, Chabrier PE. Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. Eur J Pharmacol. 2009;617:48–53.
   PubMed Web of Science ®Google Scholar
• Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage. 2014;47:166–173.
   PubMed Web of Science ®Google Scholar
• Fallon MT, Storey DJ, Krishan A, et al. Cancer treatment-related neuropathic pain: proof of concept study with menthol-a TRPM8 agonist. Support Care Cancer. 2015;23:2769–2777.
   PubMed Web of Science ®Google Scholar
• Thompson T, Whiter F, Gallop K, et al. NMDA receptor antagonists and pain relief: a meta-analysis of experimental trials. Neurology. 2019;92:e1652–62.
   PubMed Web of Science ®Google Scholar
• Park BY, Park SH, Kim WM, et al. Antinociceptive effect of memantine and morphine on vincristine-induced peripheral neuropathy in rats. Korean J Pain. 2010;23:179–185.
   PubMedGoogle Scholar
• Cavaletti G, Marmiroli P. Pharmacotherapy options for managing chemotherapy-induced peripheral neurotoxicity. Expert Opin Pharmacother. 2018;19:113–121.
   PubMed Web of Science ®Google Scholar
• Gewandter JS, Brell J, Cavaletti G, et al. Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations. Neurology. 2018;91:403–413.
   PubMed Web of Science ®Google Scholar
• Frigeni B, Piatti M, Lanzani F, et al. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the national cancer institute common toxicity scale. J Peripher Nerv Syst. 2011;16:228–236.
   PubMed Web of Science ®Google Scholar
• Gewandter JS, Dworkin RH, Finnerup NB, et al. Painful chemotherapy-induced peripheral neuropathy: lack of treatment efficacy or the wrong clinical trial methodology? Pain. 2017;158:30–33.
   PubMed Web of Science ®Google Scholar
• Alvarez P, Levine JD. Antihyperalgesic effect of tetrodotoxin in rat models of persistent muscle pain. Neuroscience. 2015;311:499–507.
   PubMed Web of Science ®Google Scholar
• Kumar R, Ryan D. Lorcaserin departs, leaving more questions than answers. Obesity. 2020;28(7):1167.
   PubMed Web of Science ®Google Scholar